Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9146.122 | 1.0774 | 1.1144 | 1.3408 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9146.122 | 1.0172 | 1.0257 | 1.3408 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9146.122 | 1.0474 | 1.0703 | 1.3408 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9146.122 | 0.9795 | 0.9694 | 1.3408 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 5903.102 | 1.0014 | 1.0023 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 5903.102 | 1.0353 | 1.0560 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 5903.102 | 0.9700 | 0.9521 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 5903.102 | 1.0181 | 1.0287 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 5903.102 | 0.9760 | 0.9616 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 5903.102 | 0.9466 | 0.9144 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 5903.102 | 0.9112 | 0.8572 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 5903.102 | 0.8788 | 0.8044 | 1.2557 | |
| BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 5903.102 | 0.8699 | 0.7898 | 1.2557 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7798.018 | 1.0352 | 1.0485 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7798.018 | 1.0380 | 1.0522 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7798.018 | 1.0429 | 1.0589 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7798.018 | 1.0809 | 1.1106 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7798.018 | 1.0092 | 1.0127 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7798.018 | 1.0068 | 1.0094 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7798.018 | 0.9711 | 0.9599 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7798.018 | 1.0587 | 1.0805 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7798.018 | 1.0020 | 1.0028 | 1.4461 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9158.123 | 1.0183 | 1.0418 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9158.123 | 1.0016 | 1.0036 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9158.123 | 1.0208 | 1.0476 | 0.8769 |